P/E ratio for BioMarin Pharmaceutical (BMRN)
P/E ratio as of March 2025 (TTM): 91.7
According to BioMarin Pharmaceutical's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 91.7408. At the end of 2022 the company had a P/E ratio of 135.
P/E ratio history for BioMarin Pharmaceutical from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 135 | -153.34% |
| 2021 | -252 | -1464.48% |
| 2020 | 18.5 | -103.06% |
| 2019 | -604 | 204.98% |
| 2018 | -198 | 46.57% |
| 2017 | -135 | 540.95% |
| 2016 | -21.1 | -78.27% |
| 2015 | -97.0 | -2.36% |
| 2014 | -99.3 | 80.75% |
| 2013 | -55.0 | 6.12% |
| 2012 | -51.8 | -26.19% |
| 2011 | -70.2 | -621.08% |
| 2010 | 13.5 | |
| 2008 | 55.6 | -125.14% |
| 2007 | -221 | 372.47% |
| 2006 | -46.8 | 373.5% |
| 2005 | -9.89 | 350.39% |
| 2004 | -2.20 | -65.19% |
| 2003 | -6.31 | 29.76% |
| 2002 | -4.86 | -40.67% |
| 2001 | -8.20 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 | -3.69 | -104.03% | 🇺🇸 USA |
 | -0.5738 | -100.63% | 🇺🇸 USA |
 | -0.5408 | -100.59% | 🇺🇸 USA |
 | 17.6 | -80.86% | 🇫🇷 France |
 | -13.1 | -114.32% | 🇺🇸 USA |
 | 22.5 | -75.53% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.